Chemokine receptor 4 targeted protein MRI contrast agent for early detection of liver metastases.
SCIENCE ADVANCES(2020)
摘要
Liver metastases often progress from primary cancers including uveal melanoma (UM), breast, and colon cancer. Molecular biomarker imaging is a new non-invasive approach for detecting early stage tumors. Here, we report the elevated expression of chemokine receptor 4 (CXCR4) in liver metastases in UM patients and metastatic UM mouse models, and development of a CXCR4-targeted MRI contrast agent, ProCA32.CXCR4, for sensitive MRI detection of UM liver metastases. ProCA32.CXCR4 exhibits high relaxivities (r(1) = 30.9 mM(-1) s(-1), r(2) = 43.2 mM (-1) s(-1) , 1.5 T; r(1) = 23.5 mM(-1) s(-1) , r(2) = 98.6 mM(-1) s(-1), 7.0 T), strong CXCR4 binding (K-d = 1.10 +/- 0.18 mu M), CXCR4 molecular imaging capability in metastatic and intrahepatic xenotransplantation UM mouse models. ProCA32.CXCR4 enables detecting UM liver metastases as small as 0.1 mm(3). Further development of the CXCR4-targeted imaging agent should have strong translation potential for early detection, surveillance, and treatment stratification of liver metastases patients.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要